News

SORT BY YEAR
23 May, 2018

Ally Bridge Portfolio News – Ally Bridge Group Leads GRAIL’s $300 Million Series C Financing

HONG KONG, May 21, 2018 /PRNewswire/ — Ally Bridge Group, a global life science-focused investment group, today announced that it has led a $300 million financing completed for GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured. “We are very impressed with the scientific, clinical, and software […]

Read More
23 May, 2018

Ally Bridge Portfolio News – GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing

MENLO PARK, Calif. & HONG KONG–(BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6 Dimensions Capital, […]

Read More
8 May, 2018

Ally Bridge Portfolio News – WUXI APPTEC PRICES A-Share IPO

Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan. The price values WuXi at RMB22.5 billion ($3.5 billion), based on […]

Read More
27 March, 2018

Ally Bridge Portfolio News – Hua Medicine Raises $117.4 Million in Series D & Series E Financing

Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million. The financing included new investors Blue Pool Capital Limited, GIC Private Limited, AVICT Global, 6 Dimensions Capital, Adrian Cheng (via K11 Investments), […]

Read More
21 March, 2018

Ally Bridge Portfolio News – Boston Scientific Announces Agreement To Acquire NxThera

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia MARLBOROUGH, Mass., March 21, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) […]

Read More
8 January, 2018

Ally Bridge Group and LifeTech Scientific Form China-Global Medtech Investment and Operating Partnership

Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK: 1302), a leading innovative medical device company in China, to focus on investing in some of the world’s leading medtech companies and helping them to […]

Read More
28 August, 2017

Synlogic Completes Merger with Mirna Therapeutics

CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Aug. 28, 2017– Synlogic, Inc. and Mirna Therapeutics, Inc. today announced that the proposed merger of the two companies has closed following the approval of Mirna’s stockholders received on August 24, 2017. The merged company will operate as Synlogic, Inc. and will focus on advancing Synlogic’s platform for development of […]

Read More
15 June, 2017

PE-backed WuXi Biologics completes Hong Kong re-listing

WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 million) IPO. The company sold 192.9 million shares at HK$20.60 apiece, according to a filing, although the size […]

Read More
25 May, 2017

Ally Bridge reaches ‘inflection point’ with Wuxi IPOs – Profiler

Ally Bridge, the healthcare investment group that whisked Shanghai-based Wuxi Pharmatech from under the noses of established global private equity firms in 2015, is “reaching an inflection point”, according to founder Frank Yu. Established five years ago Ally Bridge has matured into a larger healthcare growth capital and buyout firm via its Flagship fund, while […]

Read More
24 May, 2017

Wuxi Biologics, Wuxi Apptech’s IPOs could benefit from scarcity value – Ally Bridge founder Frank Yu

 Wuxi Biologics has ‘scarcity value’, worth 10% to 15% of group  Future HK IPO of Shandong Luoxin is possible The listings of Wuxi Biologics in Hong Kong and the remainder of WuxiPharmatech‘s assets in China will benefit from their scarcity value, according to Frank Yu, founder of Ally Bridge, the firm that led the delisting the Shanghai-based Wuxi Pharmatech from New York in 2015. Wuxi Biologics, which was incorporated in […]

Read More